That patients would rather acquire TP53 wild-type alleles than TP53 alterations under long-term DEC treatment is unlikely related to resistance but highlights the unique and incompletely understood impact of DEC on TP53-mutant AML clones. The gene discussed is TP53; the disease is acute myeloid leukemia.